In the last three months, 11 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish. The following table summarizes ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, ...

Intellia’s shares plummeted more than 20% on Nov. 7 after news that a patient treated with its pipeline candidate Nex-Z, who had been hospitalized on Oct. 24 with elevated liver enzymes, has died. The ...

Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 44% to $14.34 in early trading Monday. The ...

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, ...